Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19
Loma Linda University Health announced on Feb. 10 the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapi...





